Cargando…

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Myles, Block, Geoffrey A, Chertow, Glenn M, Cooper, Kerry, Fouqueray, Bruno, Moe, Sharon M, Sun, Yan, Tomlin, Holly, Vervloet, Marc, Oberbauer, Rainer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025329/
https://www.ncbi.nlm.nih.gov/pubmed/32082556
http://dx.doi.org/10.1093/ckj/sfz034
_version_ 1783498495877971968
author Wolf, Myles
Block, Geoffrey A
Chertow, Glenn M
Cooper, Kerry
Fouqueray, Bruno
Moe, Sharon M
Sun, Yan
Tomlin, Holly
Vervloet, Marc
Oberbauer, Rainer
author_facet Wolf, Myles
Block, Geoffrey A
Chertow, Glenn M
Cooper, Kerry
Fouqueray, Bruno
Moe, Sharon M
Sun, Yan
Tomlin, Holly
Vervloet, Marc
Oberbauer, Rainer
author_sort Wolf, Myles
collection PubMed
description BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are unknown. METHODS: To investigate potential mediators of etelcalcetide-induced FGF23 reduction, we performed secondary analyses of the 26-week randomized trials that compared the effects on PTH of etelcalcetide (n = 509) versus placebo (n = 514) and etelcalcetide (n = 340) versus cinacalcet (n = 343) in adults with sHPT receiving hemodialysis. We analyzed changes in FGF23 in relation to changes in PTH, calcium, phosphate and bone turnover markers. We also investigated how concomitant treatments aimed at mitigating hypocalcemia altered the FGF23-lowering effects of etelcalcetide. RESULTS: Etelcalcetide reduced FGF23 [median % change (quartile 1–quartile 3)] from baseline to the end of the trial significantly more than placebo [–56% (–85 to –7) versus +2% (–40 to +65); P < 0.001] and cinacalcet [–68% (–87 to –26) versus –41% (–76 to +25); P < 0.001]. Reductions in FGF23 correlated strongly with reductions in calcium and phosphate, but not with PTH; correlations with bone turnover markers were inconsistent and of borderline significance. Increases in concomitant vitamin D administration partially attenuated the FGF23-lowering effect of etelcalcetide, but increased dialysate calcium concentration versus no increase and increased dose of calcium supplementation versus no increase did not attenuate the FGF23-lowering effects of etelcalcetide. CONCLUSION: These data suggest that etelcalcetide potently lowers FGF23 in patients with sHPT receiving hemodialysis and that the effect remains detectable among patients who receive concomitant treatments aimed at mitigating treatment-associated decreases in serum calcium.
format Online
Article
Text
id pubmed-7025329
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-70253292020-02-20 Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis Wolf, Myles Block, Geoffrey A Chertow, Glenn M Cooper, Kerry Fouqueray, Bruno Moe, Sharon M Sun, Yan Tomlin, Holly Vervloet, Marc Oberbauer, Rainer Clin Kidney J CKD-Mdb BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are unknown. METHODS: To investigate potential mediators of etelcalcetide-induced FGF23 reduction, we performed secondary analyses of the 26-week randomized trials that compared the effects on PTH of etelcalcetide (n = 509) versus placebo (n = 514) and etelcalcetide (n = 340) versus cinacalcet (n = 343) in adults with sHPT receiving hemodialysis. We analyzed changes in FGF23 in relation to changes in PTH, calcium, phosphate and bone turnover markers. We also investigated how concomitant treatments aimed at mitigating hypocalcemia altered the FGF23-lowering effects of etelcalcetide. RESULTS: Etelcalcetide reduced FGF23 [median % change (quartile 1–quartile 3)] from baseline to the end of the trial significantly more than placebo [–56% (–85 to –7) versus +2% (–40 to +65); P < 0.001] and cinacalcet [–68% (–87 to –26) versus –41% (–76 to +25); P < 0.001]. Reductions in FGF23 correlated strongly with reductions in calcium and phosphate, but not with PTH; correlations with bone turnover markers were inconsistent and of borderline significance. Increases in concomitant vitamin D administration partially attenuated the FGF23-lowering effect of etelcalcetide, but increased dialysate calcium concentration versus no increase and increased dose of calcium supplementation versus no increase did not attenuate the FGF23-lowering effects of etelcalcetide. CONCLUSION: These data suggest that etelcalcetide potently lowers FGF23 in patients with sHPT receiving hemodialysis and that the effect remains detectable among patients who receive concomitant treatments aimed at mitigating treatment-associated decreases in serum calcium. Oxford University Press 2019-04-26 /pmc/articles/PMC7025329/ /pubmed/32082556 http://dx.doi.org/10.1093/ckj/sfz034 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle CKD-Mdb
Wolf, Myles
Block, Geoffrey A
Chertow, Glenn M
Cooper, Kerry
Fouqueray, Bruno
Moe, Sharon M
Sun, Yan
Tomlin, Holly
Vervloet, Marc
Oberbauer, Rainer
Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
title Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
title_full Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
title_fullStr Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
title_full_unstemmed Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
title_short Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
title_sort effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
topic CKD-Mdb
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025329/
https://www.ncbi.nlm.nih.gov/pubmed/32082556
http://dx.doi.org/10.1093/ckj/sfz034
work_keys_str_mv AT wolfmyles effectsofetelcalcetideonfibroblastgrowthfactor23inpatientswithsecondaryhyperparathyroidismreceivinghemodialysis
AT blockgeoffreya effectsofetelcalcetideonfibroblastgrowthfactor23inpatientswithsecondaryhyperparathyroidismreceivinghemodialysis
AT chertowglennm effectsofetelcalcetideonfibroblastgrowthfactor23inpatientswithsecondaryhyperparathyroidismreceivinghemodialysis
AT cooperkerry effectsofetelcalcetideonfibroblastgrowthfactor23inpatientswithsecondaryhyperparathyroidismreceivinghemodialysis
AT fouqueraybruno effectsofetelcalcetideonfibroblastgrowthfactor23inpatientswithsecondaryhyperparathyroidismreceivinghemodialysis
AT moesharonm effectsofetelcalcetideonfibroblastgrowthfactor23inpatientswithsecondaryhyperparathyroidismreceivinghemodialysis
AT sunyan effectsofetelcalcetideonfibroblastgrowthfactor23inpatientswithsecondaryhyperparathyroidismreceivinghemodialysis
AT tomlinholly effectsofetelcalcetideonfibroblastgrowthfactor23inpatientswithsecondaryhyperparathyroidismreceivinghemodialysis
AT vervloetmarc effectsofetelcalcetideonfibroblastgrowthfactor23inpatientswithsecondaryhyperparathyroidismreceivinghemodialysis
AT oberbauerrainer effectsofetelcalcetideonfibroblastgrowthfactor23inpatientswithsecondaryhyperparathyroidismreceivinghemodialysis